Skip to main content
Loading

Tactical Therapeutics, Inc

February 26, 2024
Oncology
Tactical Therapeutics, Inc
Tactical Therapeutics, Inc is a clinical stage private Co in New York, developing Carboxyamidotriazole orotate (CTO) which has shown safety and efficacy in primary brain cancer and many undruggable heavily pretreated solid cancers with resistant mutations. CTO has unique properties which allow it to succeed, e.g., - Inhibits calcium signals linked to several oncogenes, and calcium channels (multi-targeted). - Inhibits inflammatory cytokines and a perfect companion for Immunotherapies to reverse redundancy -Targets multiple cell types, and multiple genomic markers, leaving the tumor without options. - Crosses the Blood Brian Barrier. Completed three Phase 1 trials in i) Forty-four Advanced Cancer Patients with different solid refractory tumors and ii) Forty-two GBM patients- 27 Recurrent and 15 Newly diagnosed. Plan to run randomized Fast Track Orphan Drug Phase 2 in Recurrent GBM, followed by and Phase 2 trials in other solid cancers. (RCC, CRC, NSCLC, OC)
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP